Peptide safety: what FDA has said, and the risks it cannot see
As of October 15, 2026, the most specific safety information on popular peptides comes from FDA’s own compounding reviews: it reports serious adverse events with CJC-1295 and intravenous ipamorelin, immune-reaction risks with BPC-157 and injectable GHK-Cu, and no human exposure data for TB-500. Unregulated research products add risks no one measures.
What FDA says about each substance
| Substance | FDA’s words | Status |
|---|---|---|
| BPC-157 | “may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization” | No category |
| TB-500 | “FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment.” | No category |
| CJC-1295 | “serious adverse events … including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.” | No category |
| Ipamorelin | “serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility” | 503A none; 503B Category 2 |
| GHK-Cu (injectable) | “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities” | Injectable: none; non-injectable: Category 1 |
| AOD-9604 | “serious adverse events that may be associated with AOD-9604, though causality is not clear” | No category |
Two terms recur. Immunogenicity means the body may mount an immune response to the peptide or its impurities. Impurities and API characterization means it is hard to confirm the vial holds the right molecule at the right strength and nothing else.
Sourcing is a safety issue
The same peptide carries different risks depending on who made it. A licensed pharmacy answers to a state board, and a 503B facility to FDA inspection. A research-use website answers to no one; FDA’s August 24, 2026 letters to five such sellers called their products unapproved new drugs (FDA letter). See research vs prescription peptides.
Even a pharmacy-compounded product is not FDA-approved, and FDA does not review its safety, effectiveness or quality before you receive it. Ask for the pharmacy’s name, licence and beyond-use date.
IV drips: NAD+, glutathione and vitamins
NAD, glutathione, methylcobalamin and acetyl-L-carnitine are in FDA’s Category 1, so licensed pharmacies may compound them. Category 1 is not a safety finding. Drips add the risks of IV access, and long-term safety of repeated high-dose infusions has not been established in trials. See NAD+ and glutathione.
Anti-doping is a health warning too
WADA’s 2026 list prohibits BPC-157, TB-500, CJC-1295, sermorelin, tesamorelin and ipamorelin at all times. Its 2027 explanatory note, quoted by USADA, warns that “even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health” (USADA).
Questions to ask before any peptide
- Is this substance FDA-approved, in Category 1, or in neither? (Check our status table.)
- Which pharmacy compounds it, and where can I look up its licence?
- What human evidence supports this use — not mouse studies, not a blood marker?
- What will you monitor, and what result means we stop?
- Is there an approved alternative for my condition?
October 2026: what changed
- April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
- July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
- October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.
For safety: none of FDA’s safety statements above has been withdrawn. If the interim access policy lets pharmacies compound some of these peptides, it would change the legal route, not the safety record FDA has described.
Frequently asked questions
Are peptides safe?
It depends on the substance and the source. FDA has reported serious adverse events with CJC-1295 and intravenous ipamorelin, immune-reaction risks with BPC-157 and injectable GHK-Cu, and found no human exposure data for TB-500. Most peptides sold for wellness have little long-term human safety data.
Is a pharmacy-compounded peptide safer than a research peptide?
It carries fewer unknowns: a named pharmacy, a licence you can check and a prescriber. It is still not FDA-approved, and FDA does not review compounded drugs before they reach you. A research-use product has none of those checks.
What does immunogenicity mean for peptides?
It means your immune system may react to the peptide or to impurities in it. FDA flags this risk for BPC-157 by certain routes and for injectable GHK-Cu, partly because peptides can clump together (aggregate) during manufacture.
Are NAD+ and glutathione drips safe?
They are in FDA’s Category 1, which allows licensed pharmacies to compound them but is not a safety finding. Risks include those of any IV and any compounded sterile product. Long-term safety of repeated drips has not been established.
Sources
- FDA — Certain bulk drug substances for use in compounding that may present significant safety risks (page current as of April 22, 2026) (read October 15, 2026)
- FDA — Interim policy categories for 503A and 503B bulk drug substances (PDF, updated May 14, 2026) (read October 15, 2026)
- FDA — Bulk drug substances used in compounding under section 503A (page current as of May 14, 2026) (read October 15, 2026)
- FDA warning letter — Royal Peptides LLC, 734884 (August 24, 2026) (read October 15, 2026)
- World Anti-Doping Agency — Prohibited List (2026 list in force) (read October 15, 2026)
- USADA — Athlete advisory: what’s new on the 2027 WADA Prohibited List (read October 15, 2026)
- World Anti-Doping Agency — 2027 Prohibited List (published September 21, 2026; in force January 1, 2027) (read October 15, 2026)